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Neuro-Behçet’s disease (NBD) involves the central nervous system; peripheral nervous system involvement is not
often reported. NBD is quite common in adult patients and occurs rarely during childhood and adolescence. Young
patients may share symptoms and signs of NBD with other neuro-ophthalmological disorders (e.g. idiopathic
intracranial hypertension); thus, making the differential diagnosis difficult. Neuroimaging is mandatory and
necessary for a correct NBD diagnosis but in children radiological examinations are often difficult to perform
without sedation. From 1971 to 2011, 130 patients aged ≤16 years have been reported with NBD, according to
retrospective surveys, case series, and case reports. The origin of the reported cases met the well-known
geographical distribution of Behçet’s disease (BD); the mean age at presentation of neurological findings was
11.8 years, with male gender prevalence (ratio, 2.9:1). We considered in detail the neuro-ophthalmological features
of the 53 cases whose neuroimaging alterations were described with an assigned radiological pattern of the
disease (parenchymal: 14 cases, non-parechymal: 35 cases, and mixed: 4 cases). In 19/53 patients (36%),
neuro-ophthalmological symptoms anticipated any pathognomonic sign for a BD diagnosis, or only occasional
aphtae were recalled by the patients. Family history was positive in 17% of subjects. Headache was reported in 75%
of the patients; in those presenting with cerebral vascular involvement, headache was combined to other
symptoms of intracranial hypertension. Papilledema was the most frequently reported ophthalmological finding,
followed by posterior uveitis. Treatment consisted of systemic steroids in 93% of patients, often combined with
other immunosuppressive drugs (especially colchicine and azathioprine). Clinical recovery or improvement was
documented in the large majority of patients. Nine subjects had definitive alterations, and one died. Based on our
review and personal experience, a delayed diagnosis, and the consequently delayed immunosuppressive treatment,
may favour permanent sequelae, in particular, optic atrophy.Introduction
Behçet’s disease (BD) is an inflammatory, multisystem
disease named after the Turkish dermatologist who first
correlated the three characteristic findings, including re-
current oral and genital aphtae, and uveitis [1]. The cur-
rently addressed diagnostic criteria were defined in 1990
by the International Society for Behçet’s Disease [2].
However, these criteria make no specific reference to
central nervous system (CNS) involvement. This condi-
tion, usually called neuro-Behçet’s disease (NBD), has
variable prevalence depending on the series, but can rep-
resent 9–10% of affected patients [3]. Cerebral computed* Correspondence: paolo.mora@unipr.it
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reproduction in any medium, provided the ortomography (CT), magnetic resonance imaging (MRI),
magnetic resonance angiography (MRA), and functional
neuroimaging such as single-photon emission computed
tomography (SPECT) have become the reference radio-
logical tools for diagnosis and have proven particularly
useful in ruling out differential diagnoses (e.g., idiopathic
intracranial hypertension, IIH). The radiological pattern
of the disease has been divided into two major forms: 1)
the parenchymal form, which is clinically subdivided
into acute and chronic progressive; and 2) the non-
parenchymal (or vascular) form [4]. In the parenchymal
type, the acute pattern is characterised by acute menin-
goencephalitis with or without focal lesions; the chronic
progressive pattern is characterised by slowly progressive
central and peripheral alterations such as dementia,
ataxia, or dysarthria, along with a persistently marked
elevation of interleukin-6 in the cerebrospinal fluid [5-7].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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possible, but occurs secondary to pathological processes
localised in the large venous or, more rarely, arterial cere-
bral vessels [8,9]. The concomitance of parenchymal and
vascular involvement has been classified in some studies
as mixed parenchymal and non-parenchymal [3,10].
Unlike younger subjects, adult patients often develop
neurological involvement after some non-neurological
manifestations of BD [11], which greatly favours a correct
diagnosis and early treatment. Although not predominant,
neuro-ophthalmological findings in BD have been re-
ported for a long time in children, and optic atrophy is a
major consequence [12-14]. However, the prevalence of
such complications is difficult to ascertain from available
reports, mainly because of the limited number of patients
and the lack of clear details about respective neurological
findings [3]. An extensive review of the literature on
pediatric NBD, focusing on the neuro-ophthalmological
features in cases with a definitive radiological diagnosis, is
presented and discussed.
Methods
This review was designed to examine all reports concern-
ing subjects aged ≤16 years having BD and presenting with
any related CNS involvement. A diagnosis of BD was con-
sidered if it matched the international classification criteria
(Japanese or European) [2,15]. Other criteria were accepted
when they were the standard by the date of publication or
when they were based on distinctive neuroimaging.
We searched MEDLINE (October 1971–December
2011) and EMBASE (January 1980–December 2011) sin-
gly and in combination using the following key words:
Behçet, Behçet’s disease, neuro-Behçet, neurology, im-
aging, venous thrombosis, central nervous system, optic
nerve, paediatric, juvenile, and young. Articles written in
English, French, German, and Italian were fully reviewed.
Other languages were reviewed from the Abstract. The
Reference sections of the articles were reviewed for any
article that had been missed in the electronic search.
The primary outcome of this review was to evaluate
the neurological and ophthalmological features of the
disease in young patients. Secondary outcomes that were
evaluated were other aspects of the disease, in particular:
time of presentation of neuro-ophthalmological findings,
family history, drugs used for treatment, and prognosis.
Considering the difficulty of the differential diagnosis and
the problems related to classifying NBD, we decided to
limit a detailed analysis of the above mentioned outcomes
to those cases with a definitive diagnosis based on neuroi-
maging. A concise overview of the same parameters
was however performed in cases for whom a precise
radiological characterisation was not reported. The demo-
graphic data were considered for all patients described in
the literature.Results
Source literature
In total, 38 articles have reported 130 patients within the
considered range of age who were affected by BD with
neurological involvement (excluding the cases with iso-
lated headache) [12,14,16-51]. Among these articles, two
were nationwide retrospective surveys [31,32], and five
studies described eligible subjects selected from large retro-
spective chart reviews [14,30,43,48,49]. In one study, new
examinations were performed in a small cohort of subjects
[34]. The remaining studies were single-case reports or
case series.
Demographics
The demographics of all described subjects are summar-
ized in Table 1. Sixty-nine patients (53%) originated from
the so-called “silk road” stretching from Morocco to Japan
[14,17,18,28,30-33,35,37-42,44,48-50]. The large majority
of these subjects (64/69 subjects) were from Western Asia,
and only five were from other regions along this historical
route [31,41]. In addition to the large number of Asian
subjects, 24 patients (26%) were from Europe: 14 were
French [12,32,36,48], eight were Italian [29,34,46,47], and
two were from the UK [22,43]. The remaining geographical
areas had minor prevalence (see Table 1). [16,19-21,23-
27,37,45] The origins of 25 patients were not specified.
Gender was reported in 71/130 subjects, with 53 males
(75%) and 18 females. The mean age calculated from the
available data was 11.8 years.
Clinical evidences
We considered that a definitive diagnostic characterisation
was achieved in the fifty-three subjects whose neuroim-
aging (MRI, and/or MRV, and/or CT, and/or SPECT) was
clearly reported. We tabled the neuro-ophthalmological
features for each of these subjects [14,26,27,33-38,40-
42,44-48,50]. Data referring to the 14 cases having the
parenchymal form are detailed in Table 2. The 35 cases
presenting with the non-parenchymal form are described
in Table 3, and the four cases with mixed parenchymal and
non-parenchymal forms are shown in Table 4. The series
published by Koné-Paut and co-authors in 1998, 2002, and
2011 [32,51,52] were excluded from the tables because
the patients with a neurological pattern were described as
miscellaneous. The series by Uluduz and co-workers was
included as a single comprehensive item, because the
authors did not detail symptoms of distinct patients.
In 12/53 patients (23%), neurological and/or ophthalmo-
logical symptoms anticipated any other major or minor cri-
teria for a diagnosis of BD [14,26,27,33,34,36,40,44,47,48],
and in seven additional patients, only previous oral/genital
aphtae were recalled by the patient [14,35,38,41,42,45,50].
NBD was diagnosed at presentation in 13 subjects
[14,36,37], and before neurological involvement in 21
Table 1 Demographics of patients with juvenile Neuro-
Behçet disease reported in the literature from 1971 to
2011 (only when specified)
Origin No. of
Patient
Male/Female Age
(median; range)
West Asia 64 37/10 13; 10–15
Europe 24 6/2 12; 8–15
North America 8 4/4 11; 1–16
East Asia 5 4/0 10; 1–13
South/Central America 2 0/2 15; 14–16
Africa 2 2/0 15; 13–16
Total 105 53/18 12; 1–16
Table 2 Ocular and neurological characteristics of patients wi
literature from 1971 to 2011
Patient Author [Ref.] OCULAR
Signs S
1 Mitra [33] Papilledema B
2 Vignola [34] Retinal vasculitis -
3 Saltik [38] Nystagmus Uveitis D
4 Hatachi [41] Nystagmus Uveitis -
5 Kara [42] Papilledema Retinal vasculitis -
6 Pipitone [46] Papillitis (bilateral) -
Retinal vasculitis
7 Robinson [47] Papillitis (unilateral) B
8 Metreau-Vastel [48] - -
9 Metreau-Vastel [48] - B
10 Metreau-Vastel [48] - -
11 Metreau-Vastel [48] - -
14* (3 cases) Uluduz [14] - -
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tory of BD (17%) [14,35,44,48], 30 patients had a negative
family history [14,26,42,48], and information was not speci-
fied in 14 patients [27,34,36-38,40,41,45-47].
Forty patients (75%) complained of headache (persistent
or recurrent). Related CNS involvement was specified in
only 16/40 (40%) patients. Eleven of these 16 subjects (69%)
had cerebral vascular involvement (thrombosis, infarct,
haemorrhage, inflammation) with headache, nausea, vomit-
ing, and/or papilledema. Nine of the 14 patients (64%) with
parenchymal NBD had symptoms and signs suggestive
of cerebral hemispheric involvement, including encepha-
lomyelitis, hemiparesis, seizure, and mental changes. Twoth juvenile parenchymal Neuro-Behçet reported in the
NEUROLOGICAL
ymptoms Signs Symptoms
lurry vision Diplopia Aseptic meningitis Headache
Cranial nerve palsies
Aseptic meningitis Seizure
iplopia Cranial nerve palsies Headache
Encephalomyelitis
Hemiparesis
Aseptic meningitis Fever
Cranial nerve palsies Headache
Hearing impairment
Vertigo
Vomiting
Aseptic meningitis Fever
Headache
Vomiting
Encephalomyelitis Headache
lurry vision Encephalomyelitis Seizure
Vertigo
Ataxia Lapse in concentration
Hemiparesis
Meningoencephalitis
lurry vision Ataxia -
Hemiparesis
Rhombencephalitis
Rhombencephalitis Behaviour problems
Lapse in concentration
Loss of memory
Trasverse Myelitis Mental retardation
Seizure
Relapsing Myelitis (1) Headache (1)
Hemiparesis (3)
Seizure (3)
Table 3 Ocular and neurological characteristics of patients with juvenile non-parenchymal Neuro-Behçet reported in
the literature from 1971 to 2011
Patients Author [Ref.] OCULAR NEUROLOGICAL
Signs Symptoms Signs Symptoms
1 Stern [26] Papilledema Diplopia Cerebral venous thrombosis Headache
Cranial nerve palsies Vomiting
2 Kerr [27] - - Subarachnoid haemorrhage Headache
Nausea, Vomiting
Paresthesias, bilateral facial
weakness
3 Vignola [34] Papilledema Retinal vasculitis Diplopia Cerebral vasculitis Headache
4 Alper [35] Papilledema - Cerebral venous thrombosis Headache
Nausea, Vomiting
5 Budin [36] Papilledema Ptosis Diplopia Cerebral venous thrombosis Headache
6 Chaloupka [37] Papilledema - Cerebral venous thrombosis Headache
7 Can [40] Papilledema Uveitis - Cerebral venous thrombosis Dizziness
Headache
Vomiting
8 Panicker [44] Papilledema Blurry vision Diplopia Cerebral venous thrombosis Headache
Seizure
Vomiting
9 Metreau-Vastel [48] - - Cerebral venous thrombosis -
10 Metreau-Vastel [48] Retinal vasculitis Blurry vision Cerebral venous thrombosis -
11 Metreau-Vastel [48] Retinal vasculitis Blurry vision Cerebral venous thrombosis Lapse in concentration
Loss of memory
12 Yilmaz [50] Papilledema Diplopia Cerebral venous thrombosis Headache
Nausea, Vomiting
35* (23 cases) Uluduz [14] Optic atrophy (1) - Cranial nerve palsies (10) Headache (23)
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combined with meningitis. Other syndromes were reported
in four subjects: spinal cord involvement in two cases
(14%), and pure acute meningeal syndrome in two cases.
Detailed ophthalmological findings were clearly related to
the corresponding radiological pattern in only 27 recordsTable 4 Ocular and neurological characteristics of patients wi
Neuro-Behçet reported in the literature from 1971 to 2011
Patient Author [Ref.] OCULAR
Signs Symptoms
1 Budin [36] Papilledema -
2 Atkinson [45] Ptosis Papilledema Uveitis Blurry vision
3 Metreau-Vastel [48] - -
4 Metreau-Vastel [48] Retinal vasculitis -(51%). The most frequently reported sign (14 subjects, 52%)
was optic nerve head involvement, which occurred in the
form of papilledema in 12 cases (86%), unilateral neuritis in
one case (7%), and bilateral papillitis in another subject.
Ocular inflammation was reported in 11 subjects (41%), se-
lectively affecting the posterior pole of the eye (retinalth juvenile mixed parenchymal and non-parenchymal
NEUROLOGICAL
Signs Symptoms
Aseptic meningitis Headache
Cerebral venous thrombosis
Cerebral infarct Headache, Nausea, Vomiting
Cranial nerve palsies
Hemiparesis
Meningoencephalitis
Cerebral venous thrombosis
Encephalomyelitis
-
Cerebral venous thrombosis Ataxia, Behaviour problems, Hemiparesis
Encephalomyelitis
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of ocular motility (diplopia, nystagmus) was documented in
eight subjects (30%) distributed over the three forms of the
disease, and two more patients (7%) presented with ptosis.
Blurry vision was a commonly reported generic symptom.
Treatment and prognosis
An immunosuppressive therapy was reported in all patients.
Different immunosuppressive drugs, mostly in combin-
ation, were used for treatment. Details on the therapy were
available for 28 subjects (53%): steroids (oral and/or intra-
venous) were the most administered treatment (26 patients,
93%); [26,27,33-38,40-42,45-48,50] followed by colchicine
(14 patients, 52%); [35,40,42,45,48,50] azathioprine (12
patients, 44%); [34,42,46-48,50] cyclosporine (five patients,
19%); [34,37,41,46,48] methotrexate (four patients, 15%);
[36,41,45] anti-tumour necrosis factor drugs (three patients,
11%); [45-47] cyclophosphamide (two patients, 7%); [46,48]
and chlorambucil (one patient, 4%) [27]. Adjunctive treat-
ments consisted of anti-seizure medications, anti-coagu-
lants, aspirin, and acetazolamide [27,34-37,42,44,48,50].
Seven patients had relapses of the neuro-ophthalmological
symptoms and required renewal of therapy or implementa-
tion of ongoing immunosuppressive treatment. Nine sub-
jects (17%) had definitive sequelae [14,48]. Motor and
sensory sequelae, visual disturbances (blurry vision, low vis-
ual acuity, unilateral or bilateral blindness due to optic atro-
phy), personality changes with behaviour abnormalities, and
cognitive difficulties were observed. One patient presenting
with the vascular form died as a consequence of the rupture
of a cerebral aneurysm (presence of multiple aneurysms)
[27]. In the large majority of the patients, a complete recov-
ery or significant improvement was reported [14,26,33-
38,40-42,44-48,50].
In the remaining seventy-seven subjects described in the
literature, neuroimaging was not available, or not clearly
described (except for 2 patients with only an initial normal
neuro-radiological examination reported) [12,16-25,28-
32,39,43,49,51]. A distinction between parenchimal and
non-parenchiaml form was conceivable for 24 patients: 19
cases (79%) presenting the parenchimal, and 5 cases pre-
senting the non-parenchimal pattern. Ocular involvement
was reported in 60 subjects (78%) but detailed in only 19
records. Among these, diplopia, cranial nerve palsies, and
uveitis were the findings most frequently observed. Optic
atrophy was reported in 5 patients. Concerning functional
prognosis, 57% of patients showed an improvement after
immunosuppressive therapy; the remaining cases (43%)
had less satisfactory course due to poor responsiveness to
treatment, frequent relapses, or optic atrophy.
Discussion
BD typically affects young adults and is less common in
children; this may explain why the International StudyGroup Criteria apply mainly to adult patient [2,53]. Fur-
thermore, these criteria make no specific reference to
CNS involvement. In the literature, the terms “paediat-
ric” and “juvenile” are often used interchangeably. Koné-
Paut [54] used the term “paediatric” for complete forms
in paediatric-aged patients, and the term “juvenile” for
cases where BD started prior to 16 years of age but the
complete form of the disease manifested after this age.
Neurological involvement in BD was first described in
adults in 1941 [55]. Some years later, histological find-
ings were reported from the autopsy of a dermatological
case [56]. The term “Neuro-Behçet syndrome” was sug-
gested in 1954 by the Italian ophthalmologists Cavara
and D’Ermo [3]. During the following decades, patients
with BD have usually been labelled as having “neuro-
logical involvement”, as CNS involvement was consid-
ered one factor in the context of different clinical
manifestations and not as a specific characterisation of
the disease (i.e., NBD). A more precise correlation be-
tween neurological symptoms and anatomical lesions
was made possible with progress in neuroimaging. MRI,
which can be combined with angiography (MRA), repre-
sents the mainstay examination to assess the radiological
patterns that distinguish the parenchymal form (more
common in adult patients) from the non-parenchymal
or vascular form [8,57,58]. Concerning the parenchymal
involvement, MRI shows lesions mainly in the brain-
stem, basal ganglia, and white matter in adult patients
[58-60]. The most typical MRI findings appear as lesions
with high signal intensity on T2-weighted sequences
[58,60-62]. A specific study on MRI interpretation of the
parenchymal form in children stated that NBD should
be suspected in patients who have brainstem and/or
diencephalic lesions that extend along the long tracts
whether or not the lesions are associated with periven-
tricular and subcortical lesions [38]. These lesions tend
to resolve on subsequent imaging studies. MRI findings
have been reported as normal or abnormal in primary
progressive disease with silent neurological involvement
[58,62]. MRI evidence of brainstem atrophy is a well-
defined feature for late NBD [58,63,64]. Concerning the
non-parenchymal form, gadolinium-enhanced MRI and
MRA have been used to confirm the diagnosis of CVST
[65]. Compared with conventional MRI sequences,
susceptibility-weighted imaging has proven to be particu-
larly effective for detecting lesions [66]. Molecular imaging
with positron emission tomography (PET) and SPECT
may allow the characterisation of regional cerebral blood
flow and metabolism. Similar to reports in adults, SPECT
is very sensitive for detecting vascular brain involvement
in paediatric patients with BD; it may support the clinical
diagnosis, especially in children with negative findings on
a brain structural examination, and may possibly reflect
cortical diffuse low-grade inflammation better than MRI
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lobes, basal ganglia, talami, and temporal cortex, including
its mesial portion, whereas the cerebellum is the least
common hypoperfused area [67]. Temporal hypoperfusion
is found primarily in patients with seizures; hypoperfusion
of deep grey nuclei is seen mainly in patients with differ-
ent manifestations [34]. Some lesions on MRI, particularly
white matter lesions, cannot be detected with SPECT, sug-
gesting that MRI is more sensitive in this area [67].
SPECT brain perfusion imaging is performed more fre-
quently than PET and uses different tracers [68] such as
technetium-99 m hexamethylpropylene amine oxime
(99mTc-HMPAO) [69], and more recently technetium-99
m ethyl cysteinate dimer (99mTc-ECD) [70,71]. Of these
two tracers, 99mTc-HMPAO is limited by radiochemical
instability due to its rapid decomposition in vitro (it must
be used within 30 minutes of preparation) and by delayed
imaging (40 minutes after injection) [69]. Moreover, sensi-
tivity with 99mTc-ECD results in superior images, which
allow easier interpretation of brain structures [72]. Meta-
bolic PET imaging with [18]F-fluordeoxyglucose can iden-
tify decreased cerebral glucose consumption at the
parieto-occipital cortex and brainstem in neuro-BD [73].
Thus, neuroimaging is essential to substantiate the diagno-
sis of NBD. In specialized and equipped centres, the ideal
diagnostic workup of NBD includes molecular imaging as
a complementary modality to assess real involvement of
the brain, particularly considering the recent availability of
hybrid technology (PET/CT and SPECT/CT) leading to
increased diagnostic accuracy and performance. Improve-
ments in imaging after effective treatment have been docu-
mented for both MRI and SPECT [34,38].
The demographics of paediatric patients with NBD
(Table 1) confirm the well-known geographical distribu-
tion of the disease, with high prevalence in Western Asia
and Southern Europe (particularly, France and Italy).
However, reports have included all continents except for
Oceania. This review found a prevalence of male cases,
with a male/female ratio of 2.9:1. This value is definitely
closer to that reported in series addressing the neuro-
logical involvement in BD independently of the age of
appearance (i.e., adults and children) [3,4,8,14,50], than
with reports focusing specifically on paediatric BD [29-
31,49,52]. Neurological involvement appears to be strongly
related to male gender. Series specifically addressing the
ocular involvement of BD in childhood showed a nearly
two folds prevalence of males [13,74]. The mean age at
diagnosis is 11.8 years, with a median of 12 years. This
means that a peak in neurological manifestations is
observed around puberty, although the onset of the neuro-
logical disease may be observed after or before this age, in-
cluding very early childhood.
Considering the differential diagnosis challenge and
the problems related to classifying NBD, we decided tolimit a detailed analysis of the neuro-ophthalmological
findings to those cases with definitive radiological char-
acterisation. More than 20% of these young patients
complained of neuro-ophthalmological symptoms before
the typical diagnostic elements were disclosed. This per-
centage rises to >35% considering the cases with a sole
anamnestical report of oral and/or genital aphtae (not
necessarily more than three episodes per year). This pro-
portion is remarkably higher than that reported in other
non-age-related NBD series, with no specification of
whether the small number of cases with neurological
onset were the youngest patients in the series [4,43].
Family history was positive in 17% of the cases. This
proportion is in accordance with what Koné-Pout and
co-authors referred to in 1998 as “an unexpected find-
ing”, commenting on the high rate of familial cases in
their famous survey of BD in children compared with
the rate commonly reported for adult patients [32]. This
evidence was further supported by a segregation analysis
after stratification of BD families into paediatric and
non-paediatric groups, which detected a Mendelian
autosomal recessive transmission only in paediatric fam-
ilies. In contrast, no evidence for Mendelian inheritance
was observed in patients with BD and more typical age
of onset criteria [75]. Three-fourths of subjects com-
plained of headache, often associated with other alarm-
ing neurological findings such as nausea, vomiting, or
papilledema (11 of 16 detailed cases). A higher preva-
lence of headache characterised the patients with cere-
bral vascular involvement. This symptom was evidently
related to the presence of intracranial hypertension sec-
ondary to vascular complications, often consisting of
thrombosis within large veins and occasionally arteries.
No clear distinction between tension-type and migraine
headaches was expressed among the non-vascular cases.
However, the prevalence of headache in children with
NBD cannot be clearly stated as being higher than that
in the normal population. In large surveys on primary
headaches among school children in Asian and Euro-
pean populations, the prevalence of recurrent episodes
of headache ranged from 29.1% to 87.4% [76-79].
Ocular alterations were described in 21/27 cases (78%).
Optic nerve head involvement was the most frequently
reported alteration (52%), chiefly in the form of papille-
dema. Primitive ocular involvement (i.e., excluding ocular
findings secondary to neurological alterations such as
papilledema, nystagmus, and extra-ocular muscle palsies)
was reported in 12 cases (44%) as an inflammation of
the posterior segment of the eye (posterior uveitis), with
prevalence of retinal vasculitis (seven subjects). No cases
had pure anterior uveitis, although iridocyclitis, with or
without hypopyon, is considered a classic finding in BD
[80]. Among the cases with a definitive radiological char-
acterisation, the non-parenchymal form, in particular
Mora et al. Orphanet Journal of Rare Diseases 2013, 8:18 Page 7 of 9
http://www.ojrd.com/content/8/1/18with CVST, was predominant. However, this evidence is
influenced by a recent Turkish series; [14] excluding this
series, the parenchymal and non-parenchymal forms were
reported almost equally.
The prognosis was good in about 80% of cases who
experienced recovery or significant improvement of
neuro-ophthalmological alterations by the end of follow-
up, even in cases of recurrent attacks. Nine patients
(17%) had definitive visual and/or neurological sequelae.
One patient presenting with a vascular form died. The
rate of favourable prognosis was slightly worse (57%) in
cases without radiological characterisation; this evidence
is of uncertain interpretation. A possible explanation is
that the lack of pathognomonic radiological features im-
plied a delayed diagnosis and treatment. Improvement
was always obtained with a slowly tapered immunosup-
pressive regimen, and the drugs used most often were
systemic steroids, colchicine, and azathioprine, in de-
creasing order. The European League Against Rheuma-
tism (EULAR) standardised operating procedures for the
management of BD [81-83]. There are no controlled data
to guide the management of CNS involvement in BD. For
parenchymal involvement agents to be tried may include
corticosteroids, interferon α (INFα), azathioprine, cyclo-
phosphamide, methotrexate, and anti-tumour necrosis
factor drugs. For dural sinus thrombosis corticosteroids
are recommended. Cyclosporine A, due to its potential
neurotoxicity, should be avoided in patients with BD with
CNS involvement, unless necessary for intraocular inflam-
mation. Although the effectiveness of INFα in controlling
even recalcitrant manifestations of BD is well demon-
strated [84,85], no patient in this review was treated with
this drug, probably due to the young age. Any patient with
BD and inflammatory eye disease affecting the posterior
segment should be on a treatment regimen that includes
azathioprine and systemic corticosteroids. Azathioprine is
widely accepted as the initial agent for ocular involvement
of BD. Corticosteroids rapidly suppress the inflammation
but potential side effects including cataract and glaucoma
cause concern. The systematic literature research considers
about 20 randomized controlled trials (RCTs) on the man-
agement of patients with BD, but there are no studies relat-
ing to the management of gastrointestinal and neurological
involvement. Moreover, questions related to treatment of
early and pediatric form of the disease were not addressed
by EULAR’s recommendations. Another problem that has
not been adequately addressed in RCTs is whether anticoa-
gulation is required for the venous thrombosis in BD.
In our experience, as well as in at least five cases reported
in the literature (see Table 3), the non-parenchymal form
began with binocular diplopia as predominant symptom. In
these cases, diplopia was related to a peripheral ophthalmo-
plegia due to a “stretching” effect on the troncular pars of
the sixth cranial nerve at the level of Dorello’s canal,secondary to the elevated intracranial pressure (third and
fourth cranial nerve are rarely involved). However, sixth
nerve palsy remains a poorly specific sign of increased
intracranial pressure. Differential diagnosis should consider
pathologies typically responsible for intracranial hyperten-
sion, in particular IIH or CVST due to causes other than
primary vasculitis (e.g. otitis media with mastoiditis). In any
case, neuroimaging is essential to support differential diag-
nosis of acute intracranial hypertension, focussing on exclu-
sion of an expanding intracranial mass, CVST, IIH, or
impending meningitis, with decreasing frequency.
In several cases of NBD, mostly non-parenchimal forms,
early symptoms were consistent with those reported for
IIH, i.e.: pulsatile headache (possibly precipitated by
changes in posture), prolonged vomiting, pulsatile tinnitus,
transient visual obscurations, blurred vision, and diplopia.
IIH is frequently the cause of increased intracranial pres-
sure and papilledema in young adults and, sometimes, in
children. This syndrome has some characterising features,
and obesity is one of the most significant [86,87]. For this
reason, the Body Mass Index is an easily achievable para-
meter able to orient differential diagnosis in a young patient
presenting with intracranial hypertension. Also a previous
antibiotic regimen should be carefully investigated in chil-
dren; IIH may occur after a symptom-free period of weeks
following the use of different categories of antibiotics for
general infections (e.g. tetracycline, or nalidixic acid). How-
ever, to reach a definitive diagnosis of IIH the revised
Dandy’s criteria must be satisfied, as follows: 1) elevated
cerebrospinal fluid pressure with normal composition, as
documented by lumbar puncture; 2) normal neurological
examination except for papilledema and possibly sixth
nerve palsy; 3) no evidence of hydrocephalus or a mass,
structural, or vascular lesion on MRI or contrast-enhanced
CT for typical patients, or on MRI and MRA for all others;
and 4) no other cause of intracranial hypertension identified
[88]. Funduscopic examination of the optic nerve head is
strictly recommended in all cases of suspected or confirmed
elevated intracranial pressure, in order to prevent severe
visual alterations related to true papilledema [89]. From a
theoretical point of view, papilledema may produce an irre-
versible visual loss just a few weeks after intracranial hyper-
tension has been established. Actually, the amount of
axonal loss in papilledema is related to the severity and the
duration of the optic disc swelling, with severity and dur-
ation acting as independent variables.
In summary, we can conclude that increased intracra-
nial pressure, headache, papilledema, and possibly diplo-
pia owing to the involvement of the intracranial portion
of the sixth nerve represent the prevalent clinical pre-
sentations of the vascular form of NBD. Physicians should
not be tempted to diagnose IIH in the case of headache
with papilloedema without careful exclusion of all differ-
ential diagnoses. In children these symptoms could be
Mora et al. Orphanet Journal of Rare Diseases 2013, 8:18 Page 8 of 9
http://www.ojrd.com/content/8/1/18early manifestations of BD and the differential diagnosis
often requires multidisciplinary expertise (i.e. paediatric,
neurological, ophthalmological, and immunological). With
a delayed diagnosis, it may not be possible to prevent optic
atrophy even with a good control of other systemic symp-
toms. This review updates a previous database on the
topic [90] to 1989 and may assist in the interpretation of
results from upcoming large cohorts of patients who were
followed longitudinally [91].
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